EDIT Editas Medicine, Inc. - Common Stock
$2,90
السعر · أغسطس 18, 2026
البيانات الأساسية اعتبارًا من أغسطس 5, 2026
نطاق 52 أسبوعًا
$2–$5
43% of range
تقييم المحللين
BUY
18 analysts
السعر المستهدف
$6
+107% upside
P/E (TTM)
-1.6
ROE
-688.8%
هامش صافي الربح
-395.0%
حول Editas Medicine, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
اقرأ المزيد
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
EDIT لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$2.90
القيمة السوقية
$284M
P/E (TTM)
-1.6
ربح السهم (آخر 12 شهرًا)
$-1.80
الإيرادات (آخر 12 شهرًا)
$41M
عائد التوزيعات
—
ROE
-688.8%
D/E الدين/حقوق الملكية
2.1
نطاق 52 أسبوعًا
$2 – $5
EDIT مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$41M
2016-12-31
→
2025-12-31
ربح السهم
$-1.80
2019-12-31
→
2025-12-31
التدفق النقدي الحر
$-166M
2016-12-31
→
2025-12-31
الهوامش
-395.0%
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
EDIT
متوسط الأقران
P/E (TTM)
-1.6
17.4
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
7.0
52.3
P/B (السعر / القيمة الدفترية)
10.4
4.8
EV / EBITDA
-1.2
—
Price / FCF (السعر / التدفق النقدي الحر)
-1.7
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
EDIT
متوسط الأقران
Operating Margin (هامش التشغيل)
-394.9%
—
Net Profit Margin (هامش صافي الربح)
-395.0%
-670.1%
ROA (العائد على الأصول)
-60.6%
-41.1%
ROE
-688.8%
-52.6%
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
EDIT
متوسط الأقران
Debt / Equity (الدين / حقوق الملكية)
2.1
—
Current Ratio (النسبة الحالية)
3.5
7.7
Quick Ratio (النسبة السريعة)
3.5
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
EDIT
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
25.4%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
27.2%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
-14.9%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
EDIT
متوسط الأقران
EDIT توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
18 محللين
- شراء قوي 4 22,2%
- شراء 8 44,4%
- احتفاظ 4 22,2%
- بيع 2 11,1%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
8 محللين · 2026-08-16
الوسيط
$5.00
الآن
$2.90
منخفض
$1.00
مرتفع
$15.00
السعر المستهدف الوسيط
$5.00
+72,4%
السعر المستهدف المتوسط
$6.00
+106,9%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
-0.03%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 مارس، 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 ديسمبر، 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 سبتمبر، 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 يونيو، 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 مارس، 2025 | $-0.92 | $-0.60 | -0.32% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 13
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
الميزانية العمومية 24
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
التدفق النقدي 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
الربحية 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
السيولة والملاءة 4
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
الكفاءة 2
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
قائمة الدخل 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
الميزانية العمومية 24
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
التدفق النقدي 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
الربحية 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
السيولة والملاءة 4
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
الكفاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $41M | $32M | $78M | $20M | $26M |
| هامش الربح التشغيلي % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| صافي الدخل | $-160M | $-237M | $-153M | $-220M | $-193M |
| EPS المخفف | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | 2.1 | 0.4 | — | — | — |
| النسبة الحالية | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| النسبة السريعة | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $-166M | $-219M | $-137M | $-181M | $-172M |
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 239 مقدمي إقرار · $327.2M إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 41 (+2 مقابل الربع السابق) | 22 (-4 مقابل الربع السابق) | 76 (+20 مقابل الربع السابق) | 42 (-9 مقابل الربع السابق) | +75.4M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36000000 | 11111111 | 11,00% | الأسهم |
| RA CAPITAL MANAGEMENT, L.P. | $28800360 | 8889000 | 8,80% | الأسهم |
| Commodore Capital LP | $28800360 | 8889000 | 8,80% | الأسهم |
| ADAR1 Capital Management, LLC | $28800360 | 8889000 | 8,80% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $19897929 | 6141336 | 6,08% | الأسهم |
| Paradigm Biocapital Advisors LP | $18100665 | 5586625 | 5,53% | الأسهم |
| Opaleye Management Inc. | $12512653 | 3861930 | 3,82% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11658618 | 3598339 | 3,56% | الأسهم |
| Woodline Partners LP | $11519810 | 3555497 | 3,52% | الأسهم |
| Vivo Capital, LLC | $11519010 | 3555250 | 3,52% | الأسهم |
| GordonMD Global Investments LP | $10131480 | 3127000 | 3,10% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $7999298 | 2468919 | 2,45% | الأسهم |
| Logos Global Management LP | $7199280 | 2222000 | 2,20% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $7134030 | 2201290 | 2,18% | الأسهم |
| STATE STREET CORP | $7101442 | 2191803 | 2,17% | الأسهم |
| GOLDMAN SACHS GROUP INC | $6763843 | 2087606 | 2,07% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $4318842 | 1332976 | 1,32% | الأسهم |
| Seven Fleet Capital Management LP | $4310820 | 1330500 | 1,32% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $4201156 | 1296653 | 1,28% | الأسهم |
| MARSHALL WACE, LLP | $4044048 | 1248163 | 1,24% | الأسهم |
| D. E. Shaw & Co., Inc. | $3715178 | 1146660 | 1,14% | الأسهم |
| KENNEDY CAPITAL MANAGEMENT LLC | $3344111 | 1032133 | 1,02% | الأسهم |
| MACKENZIE FINANCIAL CORP | $2844856 | 878042 | 0,87% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2812424 | 868032 | 0,86% | الأسهم |
| Nantahala Capital Management, LLC | $2762748 | 852700 | 0,84% | الأسهم |
| TWO SIGMA ADVISERS, LP | $2509405 | 1224100 | 0,77% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $2407158 | 742950 | 0,74% | الأسهم |
| BlackRock, Inc. | $1813920 | 559852 | 0,55% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $1616750 | 498997 | 0,49% | الأسهم |
| Susquehanna Portfolio Strategies, LLC | $1545801 | 477099 | 0,47% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1521180 | 469500 | 0,46% | عقد خيار الشراء |
| Eversept Partners, LP | $1486541 | 458809 | 0,45% | الأسهم |
| Casdin Capital, LLC | $1441800 | 445000 | 0,44% | الأسهم |
| PEAK6 LLC | $1346029 | 415441 | 0,41% | الأسهم |
| DIADEMA PARTNERS LP | $1296000 | 400000 | 0,40% | عقد خيار الشراء |
| BIT Capital GmbH | $1056240 | 326000 | 0,32% | الأسهم |
| Cubist Systematic Strategies, LLC | $994094 | 286482 | 0,30% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878642 | 271186 | 0,27% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $751119 | 231827 | 0,23% | الأسهم |
| LPL Financial LLC | $748813 | 231115 | 0,23% | الأسهم |
| Erste Asset Management GmbH | $736000 | 230000 | 0,22% | الأسهم |
| IEQ CAPITAL, LLC | $705623 | 217785 | 0,22% | الأسهم |
| Walleye Capital LLC | $595703 | 183859 | 0,18% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558900 | 172500 | 0,17% | عقد خيار البيع |
| CITADEL ADVISORS LLC | $557604 | 172100 | 0,17% | عقد خيار البيع |
| DAFNA Capital Management LLC | $552323 | 170470 | 0,17% | الأسهم |
| Mariner, LLC | $548500 | 169291 | 0,17% | الأسهم |
| Green Alpha Advisors, LLC | $505589 | 156046 | 0,15% | الأسهم |
| PEAK6 LLC | $497340 | 153500 | 0,15% | عقد خيار الشراء |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490555 | 151406 | 0,15% | الأسهم |
| BARCLAYS PLC | $476030 | 146923 | 0,15% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $464187 | 187930 | 0,14% | الأسهم |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445030 | 137355 | 0,14% | الأسهم |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408240 | 126000 | 0,12% | الأسهم |
| Point72 Asset Management, L.P. | $405758 | 125234 | 0,12% | الأسهم |
| RHUMBLINE ADVISERS | $380421 | 117417 | 0,12% | الأسهم |
| JPMORGAN CHASE & CO | $376528 | 117665 | 0,12% | الأسهم |
| JANE STREET GROUP, LLC | $374473 | 115578 | 0,11% | الأسهم |
| FMR LLC | $348384 | 107526 | 0,11% | الأسهم |
| HSBC HOLDINGS PLC | $314481 | 97062 | 0,10% | الأسهم |
| Bank of New York Mellon Corp | $309378 | 95487 | 0,09% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $303462 | 93661 | 0,09% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300818 | 92845 | 0,09% | الأسهم |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300226 | 92094 | 0,09% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $300011 | 92596 | 0,09% | الأسهم |
| CWM, LLC | $259352 | 105001 | 0,08% | الأسهم |
| MORGAN STANLEY | $237324 | 73248 | 0,07% | الأسهم |
| CITADEL ADVISORS LLC | $229392 | 70800 | 0,07% | عقد خيار الشراء |
| OSAIC HOLDINGS, INC. | $222928 | 68806 | 0,07% | الأسهم |
| SEI INVESTMENTS CO | $221188 | 68268 | 0,07% | الأسهم |
| Nuveen, LLC | $221188 | 68268 | 0,07% | الأسهم |
| Joel Isaacson & Co., LLC | $220787 | 68144 | 0,07% | الأسهم |
| JANE STREET GROUP, LLC | $218376 | 67400 | 0,07% | عقد خيار البيع |
| SIMPLEX TRADING, LLC | $207275 | 63974 | 0,06% | الأسهم |
| MetLife Investment Management, LLC | $182140 | 56216 | 0,06% | الأسهم |
| CITIGROUP INC | $182052 | 56189 | 0,06% | الأسهم |
| CITADEL ADVISORS LLC | $173923 | 53680 | 0,05% | الأسهم |
| MML INVESTORS SERVICES, LLC | $168765 | 52088 | 0,05% | الأسهم |
| GROUP ONE TRADING LLC | $163131 | 50349 | 0,05% | الأسهم |
| Creative Planning | $147653 | 45572 | 0,05% | الأسهم |
| China Universal Asset Management Co., Ltd. | $143934 | 44424 | 0,04% | الأسهم |
| WINTON GROUP Ltd | $141588 | 43700 | 0,04% | الأسهم |
| Vanguard Global Advisers, LLC | $138876 | 42863 | 0,04% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $137376 | 42400 | 0,04% | الأسهم |
| Graham Capital Management, L.P. | $134369 | 41472 | 0,04% | الأسهم |
| Quinn Opportunity Partners LLC | $129600 | 40000 | 0,04% | الأسهم |
| Invesco Ltd. | $128178 | 39561 | 0,04% | الأسهم |
| Vanguard Personalized Indexing Management, LLC | $124108 | 38305 | 0,04% | الأسهم |
| MERCER GLOBAL ADVISORS INC /ADV | $121967 | 37644 | 0,04% | الأسهم |
| Balyasny Asset Management L.P. | $121947 | 37638 | 0,04% | الأسهم |
| AXQ CAPITAL, LP | $118104 | 36452 | 0,04% | الأسهم |
| Nuveen Asset Management, LLC | $113934 | 89712 | 0,03% | الأسهم |
| SCS Capital Management LLC | $113400 | 35000 | 0,03% | الأسهم |
| Police & Firemen's Retirement System of New Jersey | $109749 | 33873 | 0,03% | الأسهم |
| Thrive Wealth Management, LLC | $108540 | 33500 | 0,03% | الأسهم |
| TWO SIGMA SECURITIES, LLC | $107367 | 33138 | 0,03% | الأسهم |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102359 | 31207 | 0,03% | الأسهم |
| CAPTRUST FINANCIAL ADVISORS | $98159 | 30296 | 0,03% | الأسهم |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89683 | 27680 | 0,03% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88339 | 27265 | 0,03% | الأسهم |
المطلعون على الشركة 32 من المطلعين · مسؤولون 13 · مديرون 15
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3 يونيو، 2026 S | 248313 | 0 | 1 | $-41543 |
| MULLEN JAMES C | CEO | 3 يناير، 2022 S | 75898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9 فبراير، 2021 S | 43760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8 يناير، 2019 S | 1204966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 يناير، 2022 S | 31462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4 فبراير، 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 يوليو، 2026 S | 62369 | 0 | 2 | $-15133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 ديسمبر، 2021 A | 31498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 ديسمبر، 2021 A | 22675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 ديسمبر، 2021 A | 41785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 أكتوبر، 2019 A | 25000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 مارس، 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7 فبراير، 2018 A | 4000 | 0 | 0 | $0 |
| Elliott M. Levy | مدير | 17 يونيو، 2026 A | — | 0 | 0 | $0 |
| David Scadden | مدير | 17 يونيو، 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | مدير | 17 يونيو، 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | مدير | 17 يونيو، 2026 A | 22700 | 0 | 0 | $0 |
| Andrew Hirsch | مدير | 17 يونيو، 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | مدير | 3 سبتمبر، 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | مدير | 3 يونيو، 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | مدير | 15 يونيو، 2018 A | 35000 | 0 | 0 | $0 |
| Douglas G. Cole | مدير | 17 أغسطس، 2017 J | 3171 | 0 | 0 | $0 |
| Kevin Bitterman | مدير | 15 يونيو، 2017 A | 2797144 | 0 | 0 | $0 |
| Alexis Borisy | مدير | 15 يونيو، 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | مدير | 15 يونيو، 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | مالك 10% | 6 سبتمبر، 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | مالك 10% | 8 فبراير، 2016 C | 2649572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 6 أغسطس، 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 3 أغسطس، 2026 S | 14292 | 0 | 2 | $-3002 |
| Akshay Vaishnaw | — | 3 يونيو، 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 ديسمبر، 2020 M | 24907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 مارس، 2017 M | 117788 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 1 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 إيداعات | 18 سبتمبر، 2017 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 28 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32319 SH | 8 أغسطس، 2026 | يومي |
| GNOM · Global X Funds | 0,34% | 54725 NS | 31 مايو، 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341978 SH | 8 أغسطس، 2026 | يومي |
| IBB · iShares Trust | 0,03% | 1035067 SH | 8 أغسطس، 2026 | يومي |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8268 SH | 8 أغسطس، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96927 SH | 8 أغسطس، 2026 | يومي |
| BIB · ProShares Trust | 0,02% | 3611 NS | 31 مايو، 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1527 NS | 31 مايو، 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823535 SH | 8 أغسطس، 2026 | يومي |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118938 SH | 8 أغسطس، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575834 SH | 8 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,01% | 461967 SH | 8 أغسطس، 2026 | يومي |
| IWM · iShares Trust | 0,01% | 2583050 SH | 8 أغسطس، 2026 | يومي |
| RSSL · Global X Funds | 0,01% | 42610 NS | 30 إبريل، 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4633 NS | 31 مايو، 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476309 NS | 31 مايو، 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3622 NS | 31 مايو، 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32379 NS | 31 مايو، 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3660 NS | 31 مايو، 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120119 SH | 8 أغسطس، 2026 | يومي |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 مايو، 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2922 NS | 31 مايو، 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96350 NS | 31 مايو، 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19020 SH | 8 أغسطس، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1100306 SH | 8 أغسطس، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4890144 SH | 8 أغسطس، 2026 | يومي |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9046 SH | 8 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7608 SH | 8 أغسطس، 2026 | يومي |